Discover undervalued stocks with Eulerpool.

Subscribe for $2

Telix Pharmaceuticals Stock TLX.AX

Price

14.87
Today +/-
-0.29
Today %
-3.37 %

Telix Pharmaceuticals stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Telix Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Telix Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Telix Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Telix Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Telix Pharmaceuticals Stock Price History

DateTelix Pharmaceuticals Price
9/26/202514.87 undefined
9/25/202515.38 undefined
9/24/202515.55 undefined
9/23/202516.46 undefined
9/22/202515.06 undefined
9/19/202514.47 undefined
9/18/202513.66 undefined
9/17/202513.92 undefined
9/16/202514.10 undefined
9/15/202514.00 undefined
9/12/202513.76 undefined
9/11/202513.79 undefined
9/10/202514.47 undefined
9/9/202513.82 undefined
9/8/202513.55 undefined
9/5/202513.93 undefined
9/4/202513.73 undefined
9/3/202514.21 undefined
9/2/202514.29 undefined
9/1/202514.85 undefined

Telix Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Telix Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Telix Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Telix Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Telix Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Telix Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Telix Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Telix Pharmaceuticals’s growth potential.

Telix Pharmaceuticals Revenue, EBIT and net profit per share

DateTelix Pharmaceuticals RevenueTelix Pharmaceuticals EBITTelix Pharmaceuticals Net Income
2030e2.84 B undefined0 undefined606.74 M undefined
2029e2.43 B undefined632.93 M undefined409.27 M undefined
2028e2.14 B undefined483.68 M undefined294.25 M undefined
2027e1.66 B undefined205.19 M undefined132.64 M undefined
2026e1.32 B undefined122.31 M undefined61.9 M undefined
2025e1.09 B undefined62.72 M undefined40.39 M undefined
2024512.53 M undefined52.29 M undefined32.67 M undefined
2023328.87 M undefined11.53 M undefined3.41 M undefined
2022104.77 M undefined-59.43 M undefined-68.11 M undefined
20217.6 M undefined-76.95 M undefined-80.51 M undefined
20205.21 M undefined-35.6 M undefined-44.89 M undefined
20193.49 M undefined-28.36 M undefined-27.87 M undefined
2018195,100 undefined-17.51 M undefined-13.83 M undefined
20170 undefined-6.16 M undefined-6.38 M undefined

Telix Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
201720182019202020212022202320242025e2026e2027e2028e2029e2030e
0000.010.010.10.330.511.091.321.662.142.432.84
---66.6740.001,385.71215.3856.10113.2820.7926.1628.7913.5316.69
--10,533.3360.0071.4359.6262.5061.7228.9423.9618.9914.7512.9911.13
0003562205316000000
-6-13-27-44-80-683324061132294409606
-116.67107.6962.9681.82-15.00-104.41966.6725.0052.50116.39122.7339.1248.17
127.99202.12233.44257.27282.21310.64323.71345.19000000
- - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Telix Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Telix Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (k)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
20172018201920202021202220232024
               
48.7625.7744.677.9522.0476.1380.65464.85
000.750.160.7325.7542.3991.25
0012.2614.0320.124.35.0112.79
00.640.540.633.455.5511.3324.96
0.451.010.530.861.211.6425.27.25
49.2127.4258.6893.6347.54113.36164.57601.11
0.010.231.94.826.3312.3319.9535.55
0000008.0236.71
01.170.080.180.210.210.380
1.5136.3137.7254.9751.6334.9968.59202.53
03.144.224.224.13.613.1769.79
0.0400002.613.3846.67
1.5540.8543.9364.1962.2753.74113.51391.24
50.7568.27102.61157.82109.81167.1278.08992.35
               
55.5672.05115.94167.06170.84242.76292.04390.53
00000000
-6.27-19.2-45.8-88.34-167.53-190.04-190.46-42.5
00.05-0.060.3-1.15-0.37-3.5427.66
000000-0.59-3.85
49.2952.970.0879.022.1652.3697.45371.84
0.283.256.965.8111.881121.4944.96
0.250.480.450.4811.4920.813647.9
0.593.382.7212.913.9823.7649.51109.63
345.40000000
01.130.490.770.630.421.0214.06
1.478.2410.6319.9637.9855.99108.02216.55
00.61.641.441.916.4210.4366.44
0.334.373.1700006.14
010.5917.0957.4167.7752.3449.831.39
0.3315.5621.958.8569.6758.7660.19403.96
1.823.832.5378.8107.66114.75168.21620.51
51.0976.71102.61157.82109.81167.1265.66992.35
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Telix Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Telix Pharmaceuticals's financial health and stability.

Assets

Telix Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Telix Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Telix Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Telix Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
00000-1040
0000050
0000000
019111218-14
00000350
0000000
00000-2-10
-6-20-231-59-6323
0000-1-13-10
0-20-1-2-16-25
0-200-1-3-14
0000000
00-10013
580453531816
5404234217410
-2.00--1.00---7.00-
0000000
42-45-1324-1271356
-6.04-20.75-23.81.64-60.67-77.8313.09
0000000

Telix Pharmaceuticals stock margins

The Telix Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Telix Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Telix Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Telix Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Telix Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Telix Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Telix Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Telix Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Telix Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Telix Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Telix Pharmaceuticals Margin History

Telix Pharmaceuticals Gross marginTelix Pharmaceuticals Profit marginTelix Pharmaceuticals EBIT marginTelix Pharmaceuticals Profit margin
2030e61.79 %0 %21.37 %
2029e61.79 %26.01 %16.82 %
2028e61.79 %22.57 %13.73 %
2027e61.79 %12.33 %7.97 %
2026e61.79 %9.27 %4.69 %
2025e61.79 %5.74 %3.7 %
202461.79 %10.2 %6.37 %
202362.56 %3.5 %1.04 %
202259.29 %-56.72 %-65.01 %
202166.46 %-1,012.97 %-1,059.9 %
202061.17 %-682.89 %-861.06 %
201927.03 %-813.74 %-799.63 %
201861.79 %-8,972.32 %-7,088.57 %
201761.79 %0 %0 %

Telix Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Telix Pharmaceuticals earnings per share therefore indicates how much revenue Telix Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Telix Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Telix Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Telix Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Telix Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Telix Pharmaceuticals Revenue, EBIT and net profit per share

DateTelix Pharmaceuticals Sales per ShareTelix Pharmaceuticals EBIT per shareTelix Pharmaceuticals Earnings per Share
2030e8.22 undefined0 undefined1.76 undefined
2029e7.05 undefined0 undefined1.19 undefined
2028e6.21 undefined0 undefined0.85 undefined
2027e4.82 undefined0 undefined0.38 undefined
2026e3.82 undefined0 undefined0.18 undefined
2025e3.17 undefined0 undefined0.12 undefined
20241.48 undefined0.15 undefined0.09 undefined
20231.02 undefined0.04 undefined0.01 undefined
20220.34 undefined-0.19 undefined-0.22 undefined
20210.03 undefined-0.27 undefined-0.29 undefined
20200.02 undefined-0.14 undefined-0.17 undefined
20190.01 undefined-0.12 undefined-0.12 undefined
20180 undefined-0.09 undefined-0.07 undefined
20170 undefined-0.05 undefined-0.05 undefined

Telix Pharmaceuticals business model

Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Telix Pharmaceuticals SWOT Analysis

Strengths

Telix Pharmaceuticals Ltd has a strong portfolio of innovative and advanced radiopharmaceutical products.

The company has established strategic partnerships with leading healthcare organizations, which enhances its market presence.

Telix Pharmaceuticals Ltd has a highly skilled workforce with deep expertise in radiopharmaceutical development and commercialization.

Weaknesses

The company is heavily dependent on the success of its research and development efforts, which may lead to unpredictable outcomes.

Telix Pharmaceuticals Ltd faces certain regulatory and compliance challenges in different markets, potentially affecting its growth prospects.

Limited financial resources may restrict the company's ability to expand and invest in new projects.

Opportunities

The global radiopharmaceutical market is expected to witness significant growth, providing Telix Pharmaceuticals Ltd with opportunities to expand its market share.

Advancements in technology and increasing adoption of targeted molecular imaging offer Telix Pharmaceuticals Ltd chances to develop innovative radiopharmaceutical products.

Growing awareness of personalized medicine and the potential benefits of radiopharmaceuticals present opportunities for Telix Pharmaceuticals Ltd to capitalize on.

Threats

Competition from established pharmaceutical companies and emerging startups pose threats to Telix Pharmaceuticals Ltd's market position.

Stringent regulations and reimbursement policies in the healthcare industry may impact the pricing and availability of radiopharmaceutical products, affecting the company's profitability.

The ongoing COVID-19 pandemic has disrupted healthcare systems worldwide, which could cause delays in clinical trials or market launches of Telix Pharmaceuticals Ltd's products.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Telix Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Telix Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Telix Pharmaceuticals shares outstanding

The number of shares was Telix Pharmaceuticals in 2024 — This indicates how many shares 345.188 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Telix Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Telix Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Telix Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Telix Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Telix Pharmaceuticals.

Telix Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20250.3 0.37  (23.79 %)2025 Q2
12/31/20240.17 0.06  (-65.81 %)2024 Q4
6/30/20240.13 0.09  (-30.1 %)2024 Q2
12/31/20230.08 0.06  (-25.43 %)2023 Q4
6/30/20230.03 -0.05  (-233.14 %)2023 Q2
12/31/2022-0.05 -0.1  (-105.94 %)2022 Q4
6/30/2022-0.11 -0.23  (-120 %)2022 Q2
12/31/2021-0.08 -0.17  (-117.22 %)2021 Q4
6/30/2021-0.1 -0.12  (-17.77 %)2021 Q2
12/31/20200 -0.1  (0 %)2020 Q4
1

Eulerpool ESG Scorecard© for the Telix Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

60/ 100

🌱 Environment

35

👫 Social

68

🏛️ Governance

76

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees49
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Telix Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
6.56888 % Gnosis Verwaltungsgesellschaft mbH22,675,00002/6/2025
6.14978 % Behrenbruch (Christian P. Ph.D.)21,228,29806/18/2025
3.75715 % State Street Global Advisors Australia Ltd.12,969,2421,813,0273/31/2025
3.17137 % Grand Decade Developments Ltd.10,947,18102/6/2025
2.34140 % The Vanguard Group, Inc.8,082,2236,6997/31/2025
1.59237 % Vanguard Investments Australia Ltd.5,496,685-606/30/2025
1.57225 % UV-Cap GmbH & Co KG5,427,233-2,027,2672/6/2025
1.37796 % Norges Bank Investment Management (NBIM)4,756,547-1,376,72712/31/2024
1.13083 % RBC Global Asset Management (Asia) Limited3,903,5031,592,9936/30/2025
1.05124 % Nelson (Mark)3,628,750012/31/2024
1
2
3
4
5
...
10

Telix Pharmaceuticals Executives and Management Board

Dr. Christian Behrenbruch

Telix Pharmaceuticals Group Chief Executive Officer, Managing Director, Executive Director (since 2017)
Compensation 1.41 M

Mr. Darren Smith

Telix Pharmaceuticals Group Chief Financial Officer
Compensation 1.22 M

Dr. David Cade

Telix Pharmaceuticals Group Chief Medical Officer (since 2024)
Compensation 1.07 M

Mr. Richard Valeix

Telix Pharmaceuticals Group Chief Commercial Officer
Compensation 1.01 M

Dr. Darren Patti

Telix Pharmaceuticals Group Chief Operating Officer
Compensation 930,735
1
2
3

Telix Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Eckert & Ziegler Strahlen Stock
Eckert & Ziegler Strahlen
SupplierCustomer0,810,620,790,790,340,77
Merck Stock
Merck
SupplierCustomer0,750,42-0,030,640,660,91
Mauna Kea Technologies O Stock
Mauna Kea Technologies O
SupplierCustomer0,680,330,090,60 -0,44
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group
SupplierCustomer0,660,520,510,700,10-0,10
Heidelb Ph Stock
Heidelb Ph
SupplierCustomer0,660,26-0,68-0,29-0,270,34
Yantai Dongcheng Biochems A Stock
Yantai Dongcheng Biochems A
SupplierCustomer0,380,490,650,800,06-0,61
Amgen Stock
Amgen
SupplierCustomer0,340,57-0,58-0,55-0,51-0,51
HSBC Holdings Stock
HSBC Holdings
SupplierCustomer0,230,470,56-0,36-0,150,61
Cardinal Health Stock
Cardinal Health
SupplierCustomer0,050,48-0,59-0,72-0,62-0,01
JPMorgan Chase Stock
JPMorgan Chase
SupplierCustomer-0,180,430,810,820,490,86
1

Most common questions regarding Telix Pharmaceuticals

What values and corporate philosophy does Telix Pharmaceuticals represent?

Telix Pharmaceuticals Ltd represents a strong commitment to improving the diagnosis and treatment of cancer. With a focus on molecularly targeted radiation therapy, the company aims to develop innovative radiopharmaceuticals that can deliver more precise and effective cancer treatments. Telix Pharmaceuticals embraces a patient-centered approach, continually striving to enhance patient outcomes and improve quality of life. The company is dedicated to fostering collaborations, driving scientific advancements, and delivering transformative therapies to individuals battling cancer. Telix Pharmaceuticals Ltd stands as a beacon of innovation, aiming to revolutionize the field of cancer medicine with its cutting-edge technologies and unwavering dedication to making a difference.

In which countries and regions is Telix Pharmaceuticals primarily present?

Telix Pharmaceuticals Ltd primarily operates in several countries and regions, including Australia, the United States, Europe, and Japan.

What significant milestones has the company Telix Pharmaceuticals achieved?

Telix Pharmaceuticals Ltd has achieved several significant milestones. Firstly, the company successfully completed its Phase III clinical trial for TLX591-CDx, a prostate cancer imaging agent. Additionally, Telix Pharmaceuticals received regulatory approval in the United States, Europe, and Canada for TLX591-CDx, allowing for its commercialization. Another notable achievement is the successful completion of a collaboration agreement with China Grand Pharma, expanding Telix's presence in the Chinese market. Furthermore, Telix Pharmaceuticals entered into a licensing agreement with ANMI SA, enhancing its product portfolio for molecular imaging. These achievements highlight Telix Pharmaceuticals' commitment to developing innovative solutions in the field of radiopharmaceuticals.

What is the history and background of the company Telix Pharmaceuticals?

Telix Pharmaceuticals Ltd is an innovative biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for cancer diagnosis and treatment. Established in 2016, Telix has rapidly grown into a global player in the molecularly targeted radiation therapy field. The company has successfully acquired and developed a diverse portfolio of diagnostic and therapeutic products, leveraging its cutting-edge technology and strategic partnerships. Telix has made significant progress in clinical trials, regulatory approvals, and commercialization efforts, demonstrating its commitment to improving patient outcomes in oncology. With its dedicated team and robust pipeline, Telix Pharmaceuticals Ltd is poised to revolutionize cancer management through personalized and targeted radiopharmaceuticals.

Who are the main competitors of Telix Pharmaceuticals in the market?

The main competitors of Telix Pharmaceuticals Ltd in the market are other pharmaceutical companies operating in the same sector, focusing on molecularly targeted radiation (MTR) therapies and diagnostic imaging products for oncology. These competitors include established players such as Advanced Accelerator Applications SA (a Novartis company), Bayer AG, Curium Pharmaceuticals, and Progenics Pharmaceuticals. Telix Pharmaceuticals Ltd distinguishes itself through its innovative radiopharmaceutical solutions, strategic collaborations, and ongoing clinical trials.

In which industries is Telix Pharmaceuticals primarily active?

Telix Pharmaceuticals Ltd is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Telix Pharmaceuticals?

The business model of Telix Pharmaceuticals Ltd revolves around the development and commercialization of molecularly targeted radiation (MTR) products. As a leading biopharmaceutical company, Telix focuses on producing innovative diagnostic and therapeutic solutions for patients suffering from cancer. By utilizing its expertise in radiopharmaceuticals and molecular targeting, Telix aims to enhance the precision and efficacy of cancer diagnosis, imaging, and treatment. Through collaborations with various partners, Telix strives to bring advanced diagnostic imaging technologies and personalized treatment options to healthcare professionals and patients worldwide. Telix Pharmaceuticals Ltd plays a crucial role in improving patient outcomes and advancing the field of nuclear medicine.

What is the P/E ratio of Telix Pharmaceuticals 2025?

The Telix Pharmaceuticals P/E ratio is 127.1.

What is the P/S ratio of Telix Pharmaceuticals 2025?

The Telix Pharmaceuticals P/S ratio is 4.7.

What is the Quality Investing of Telix Pharmaceuticals?

The Quality Investing for Telix Pharmaceuticals is 3/10.

What is the revenue of Telix Pharmaceuticals 2025?

The expected Telix Pharmaceuticals revenue is 1.09 B AUD.

How high is the profit of Telix Pharmaceuticals 2025?

The expected Telix Pharmaceuticals profit is 40.39 M AUD.

What is the business model of Telix Pharmaceuticals

Telix Pharmaceuticals Ltd is an Australian biotechnology company specializing in the development and commercialization of diagnostic technologies and therapeutic products for oncology.

What is the Telix Pharmaceuticals dividend?

Telix Pharmaceuticals pays a dividend of 0 AUD distributed over payouts per year.

How often does Telix Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Telix Pharmaceuticals or the company does not pay out a dividend.

What is the Telix Pharmaceuticals ISIN?

The ISIN of Telix Pharmaceuticals is AU000000TLX2.

What is the Telix Pharmaceuticals WKN?

The WKN of Telix Pharmaceuticals is A2H7JK.

What is the Telix Pharmaceuticals ticker?

The ticker of Telix Pharmaceuticals is TLX.AX.

How much dividend does Telix Pharmaceuticals pay?

Over the past 12 months, Telix Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Telix Pharmaceuticals is expected to pay a dividend of 0 AUD.

What is the dividend yield of Telix Pharmaceuticals?

The current dividend yield of Telix Pharmaceuticals is .

When does Telix Pharmaceuticals pay dividends?

Telix Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Telix Pharmaceuticals?

Telix Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Telix Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Telix Pharmaceuticals located?

Telix Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Telix Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Telix Pharmaceuticals from 9/30/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/30/2025.

When did Telix Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/30/2025.

What was the dividend of Telix Pharmaceuticals in the year 2024?

In the year 2024, Telix Pharmaceuticals distributed 0 AUD as dividends.

In which currency does Telix Pharmaceuticals pay out the dividend?

The dividends of Telix Pharmaceuticals are distributed in AUD.

All fundamentals about Telix Pharmaceuticals

Our stock analysis for Telix Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Telix Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.